it shows on yahoo finance...19M.
PBMD went up today on good results from 2nd TRIAL PATIENT. The phase II is not even over yet !!
Remember AVXL is open label...so we can get good news at any time on progress.
this is crazy...once AVXL gets orphan it should go up 100%.
but it does give a very strong case for partnerships...much more inventive for partners.
could be because 2a is not based on Epilepsy, but AZ...any good news, interim data on AZ would have had a much more positive effect.
that will give AVXL a 400 million market cap...still not expensive by any measure for the market they are going for, with very little competition, and current drugs very old.
how would they have money to burn on additional trials then ? partnership ? secondary offering ?
in addition to AZ ? Or are they ?
PTBI is gene therapy..and gene therapy does not work. Check out CLDN.
We Are Initiating Coverage of Anavex with a Buy Rating and $7.00 Price Target. Anavex has a novel drug technology with several applications in central nervous system (CNS) conditions and cancers. The first indication is Alzheimer’s disease, in which the company plans to start a phase I/II trial in late 2014/early 2015. Additional research has shown potential in Parkinson’s disease, depression, epilepsy, stroke, pain, and solid tumors.
The Lead Alzheimer’s Drug Has Unique and Synergistic Mechanisms of Action. Anavex Plus is a drug that combines the company’s proprietary Anavex 2-73 molecule with generic Aricept (donepezil). Anavex 2-73 appears to reduce the accumulation of toxic proteins within cells, a key event early in the process of cellular dysfunction and disease pathways. This is a differentiated mechanism of action from the typical approaches of prior failed molecules, which have not shown benefits in Alzheimer’s disease.
Synergistic Effect with an Established Drug. Preclinical trials of Anavex 2-73 demonstrated that it prevents cell death, protects against cell damage, and results in improved memory. Donepezil, the most widely prescribed drug for Alzheimer’s, works by extending the action of neurotransmitters in surviving brain neurons. Study data have shown that the combination of both drugs may provide an 80% improvement over donepezil alone.
An Alzheimer’s Therapy Would Serve a Large Market. There are an estimated 5.2 million people with Alzheimer’s disease in the US and 11 million worldwide. Disabilities accumulate for the remainder of patients’ lives, requiring increasing care and higher medical expenses, so any therapy that has a benign AE profile and benefits is welcome in the space.
Anavex’s Pipeline Is Based on Sigma Receptor Technology. The company’s drug discovery platform is based on interactions of the sigma receptor, an intracellular receptor that activates several key pathways in the cell. Turning these pathways on or off has potential
There was a seven-point improvement in cognitive response in a three-month period, and a 5.5 point improvement after 26 weeks (as can be seen on this chart from the company's corporate presentation in early February). Why is this so encouraging? This test is strictly focused on symptomatic, not actual treatment to inhibit the disease. This cocktail has the ability to provide symptomatic relief, but also may be used for disease modification. There is no drug like that today. There is more potential to this drug than just symptomatic relief, though. The "cocktail" had a much higher response rate than Aricept (generic-donepezil) as a standalone.
The company is at the stage now where it is getting ready to run human trials in a combined 1b/2a clinical study. This study will get underway the first half of 2014, and should be put in the place fairly quickly. The trial will run three months (this is the company's highest Delta so far), six months and on to 12 months. After this trial is over, the company will need to run one more trial before it would qualify for FDA approval.
If trial results from this first three months look promising, I would not be surprised if Big Pharma took notice of this little company.
PRAN drugs work to prevent a build up of beta-amyloid deposits (well, it didn't work)....AVXL is approaching this differently ?
is it the sigma-1 receptors ?